Biodesix margins reach 82%

Biodesix said August 5 that its second-quarter gross margin reached 82%, up 200 basis points from a year earlier, as the lung diagnostics company pushed more tests through its labs at better unit economics. The Louisville, Colorado-based company reported $26.9 million in revenue for the quarter ended June 30, up 34% from a year earlier, while diagnostic testing revenue rose 42% to $25.4 million. Chief Executive Scott Hutton said the margin gain came from higher testing volume, improved average revenue per test and continued laboratory optimization. The results extended a recent stretch of gross margins at or above 80%, according to the company. ### How did Biodesix get to 82% gross margin? Biodesix processed about 20,900 diagnostic tests in the second quarter, a 38% increase from a year earlier, the company said. That volume growth lifted fixed-cost absorption across the lab network, while improved average revenue per test added to the margin expansion, according to the earnings release. The company also said laboratory workflow changes lowered cost per test. (biospace.com) Scott Hutton said in the release that Biodesix delivered “another strong quarter,” citing 34% revenue growth, 42% growth in diagnostic testing revenue and gross margins that increased to 82%. Hutton also said operating expenses excluding direct costs rose 7% while diagnostic testing volumes climbed 38%, which he described as operating leverage. (investors.biodesix.com) ### Which parts of the business drove the quarter? Diagnostic testing remained the main engine. Biodesix said diagnostic testing revenue reached $25.4 million in the quarter, compared with total revenue of $26.9 million. The company said the increase was driven by higher test volumes and higher average revenue per test year over year. (biospace.com) Yahoo Finance’s summary of the earnings call said Biodesix reported notable adoption from primary care, up 133%, and from pulmonology, up 31%, indicating broader use across ordering channels. That account also said the company posted its fifth consecutive quarter with gross margin at or above 80%. ### Was the margin gain only about pricing? (investors.biodesix.com) The company said the improvement was not only a pricing story. Biodesix attributed the margin expansion to a mix of higher average revenue per test and lower cost per test from laboratory optimization. In first-quarter results released in May, the company used similar language, saying gross margin expansion reflected higher diagnostic testing volumes, improved average revenue per test and continued optimization of laboratory workflows. (finance.yahoo.com) Second-quarter operating expenses excluding direct costs were $27.4 million, up 7% from a year earlier, according to third-party earnings summaries based on the company’s report. That growth was slower than revenue growth, which helped narrow losses and improve adjusted EBITDA year over year, those summaries said. ### What does Biodesix say comes next? (investors.biodesix.com) Biodesix maintained full-year 2026 revenue guidance of $108 million to $114 million, with the midpoint implying 25% growth, the company said. The company also said it would continue to focus on clinical evidence, reimbursement, commercial execution and expense management as it works toward profitability. (tradingkey.com) August 5 was also the date of the company’s second-quarter earnings call, which began at 4:30 p.m. Eastern, according to Biodesix’s investor relations page. Biodesix is next scheduled to participate in Canaccord Genuity’s 46th Annual Growth Conference after announcing that event on August 4. (investors.biodesix.com) (biospace.com)